Trial Profile
A Phase 1b expansion study of ARGX-110 in patients with different subtypes of relapsed/refractory cutaneous T-cell lymphoma (CTCL)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2017
Price :
$35
*
At a glance
- Drugs Cusatuzumab (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions
- 22 Jun 2017 New trial record
- 14 Jun 2017 Results (n=16) published in an argenx Media Release
- 14 Jun 2017 Updated data from trial presented at the International Conference of Malignant Lymphoma (ICML) 2017, as reported in an argenx media release.